Bili Wu,Bo Liu,Xueyan Jiang,Ye Yuan,Wan Qin,Kai Qin,Qi Mei,Li Zhang,Huilan Zhang,Guangyuan Hu,Xianglin Yuan. Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies. Oncol Transl Med, 2021, 7: 108-114.
Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies
Received:April 03, 2021  Revised:June 17, 2021
View Full Text  View/Add Comment  Download reader
KeyWord:coronavirus disease (COVID-19); cancer; immunoglobulin (Ig) G; IgM
Author NameAffiliationE-mail
Bili Wu Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology billywu2020@outlook.com 
Bo Liu Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Xueyan Jiang Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Ye Yuan Department of Gastroenterology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Wan Qin Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Kai Qin Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Qi Mei Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Li Zhang Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Huilan Zhang Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Guangyuan Hu Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology  
Xianglin Yuan Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China yuanxianglin@hust.edu.cn 
Hits: 1613
Download times: 1830
Abstract:
      Objective: The aim of this study was to examine the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients with cancer and followed up changes in SARS-CoV-2-specific antibodies to explore the impact of anti-tumor treatment in patients. Methods: Patients with cancer who visited the Outpatient Clinic of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China between March 9 and April 30, 2020 were enrolled in this retrospective cohort study. SARS-CoV-2 immunoglobulin (Ig) G, IgM, and viral load at various time points during the disease course were determined. Results: We examined the serological results of 779 patients with cancer. The overall seroprevalence (IgG-positive or IgM-positive) rate of SARS-CoV-2 was 3.4%. The probability of seropositivity was significantly higher in patients with gastric cancer than in those without gastric cancer (odds ratio: 6.349, 95% confidence interval: 2.191–18.396). Follow-up data showed that SARS-CoV-2 IgM and IgG levels decreased and the polymerase chain reaction test result remained negative in seropositive patients with cancer. Conclusion: This study investigated the seroprevalence of SARS-CoV-2 in coronavirus disease (COVID- 19)-positive patients with cancer in Wuhan, China. The seropositivity in patients with cancer was lower than or similar to that in the general population. Irrespective of anti-tumor therapy, the levels of SARS-CoV-2 antibodies decreased in these patients. More studies are needed to better understand the impact of antitumor therapy on change in the levels of SARS-CoV-2 antibodies.
Close